Table 1.
Characteristics of PLWH enrolled in the study (N = 299)
| Whole population n = 299 | |
|---|---|
| Sex, n (%) | |
| Male | 226 (75.6) |
| Female | 73 (24.4) |
| Age,years,median (IQR) | 52 (44–60) |
| Caucasian,n (%) | 269 (90.0) |
| Risk factor,n (%) | |
| MSM | 138 (46.2) |
| Heterosexual | 118 (39.5) |
| PWID | 15 (5.0) |
| Unknown/others | 28 (9.3) |
| Time since HIV diagnosis,years,median (IQR) | 12.0 (7.3–20.1) |
| Time on ART,years,median (IQR) | 10.6 (7.2–15.7) |
| BMI,median (IQR) | 25.0 (21–28) |
| Smoking habitsa, n (%) | 154 (51.5) |
| Currently smoking | 152 (50.8) |
| Quit smoking | 2 (0.67) |
| Alcohol useb, n (%) | 133 (44.5) |
| CD4 cell count nadir,cells/mm3, median (IQR) | 214 (72–340) |
| Zenith HIV-RNA,Log10copie/mL,median (IQR) | 5.04 (4.46–5.46) |
| CD4 cell count,cells/mm3, median (IQR) | 690 (491–874) |
| CD8 cell count,cells/mm3, median (IQR) | 662 (503–878) |
| CD4/CD8 ratio,median (IQR) | 1.01 (0.76–1.38) |
| HIV-RNA TND (0 copy/mL),n (%) | 292 (97.7) |
| Past AIDS-defining events,(CDC C),n (%) | 78 (26.1) |
| History of cardiovascular diseasesc, n (%) | 48 (16.1) |
| History of cancerd, n (%) | 30 (10.0) |
| Co-infection,n (%) | |
| HCV Co-infection e | 37 (12.4) |
| HBV Co-infection f | 5 (1.7) |
| Comorbidities,n (%) | |
| Hypertension | 44 (14.7) |
| Diabetes | 16 (5.4) |
| Psychiatric | 44 (14.7) |
| ART,n (%)g | |
| Triple regimen | 156 (52.8) |
| 2NRTIs + INSTI | 98 (63.3) |
| FTC/TAF/BIC | 76 (77.5) |
| FTC/TAF + DTG | 14 (14.3) |
| FTC/TAF + RGV | 8 (8.2) |
| 2NRTIs + NNRTI | 43 (27.2) |
| FTC/TAF/RPV | 25 (58.1) |
| 3TC/TDF/DOR | 18 (41.9) |
| 2NRTIs + PI/b | 15 (9.5) |
| FTC/TAF/DRV/COBI | |
| Dual regimen | 141 (47.2) |
| NRTI + INSTI | 133 (95.0) |
| 3TC/DTG | 133 (100.0) |
| NRTI + PI/b | 8 (5.0) |
| 3TC + DRV/COBI | 8 (100.0) |
| Concomitant drugs,n (%) | |
| Statins | 31 (10.4) |
| Vitamins | 67 (22.4) |
| Lipid Nutritional Supplements | 50 (16.7) |
| NSAIDs | 7 (2.3) |
| Lipid profile,median (IQR) | |
| Cholesterol,mg/dL | 182 (154–205) |
| Triglycerides,mg/dL | 104 (74–151) |
| HDL,mg/dL | 46 (39–54) |
| Previous bliph, n (%) | 121 (40.5) |
| Previous failurei, n (%) | 85 (28.4) |
| Time since last detectable viral load (≥ 50cps/mL),years,median (IQR) | 7.9 (5.0-12.1) |
| Cumulative time with viral load < 50cps/mL,years,median (IQR) | 9.04 (5.9–13.2) |
Abbreviations BMI: Body mass index; PWID: people who inject drugs; MSM: Men who have sex with men; ART: Antiretroviral therapy; HCV: Hepatitis C; HBV: Hepatitis B; THN: target not detected; NRTIs: Nucleoside reverse transcriptase inhibitors; NNRTIs; Non-nucleoside reverse transcriptase inhibitors; INSTIs: Integrase Inhibitors; PI: Protease Inhibitor. NSAIDs: Non-steroid anti-inflammatory drugs
a An adult who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes and who had quit smoking in the previous 6 months. All the current smokers smoke ≥ 10 cigarettes per day; b ≥2 alcoholic unit/day; c Includes cardiomyopathy, ischaemic stroke and myocardial infarction; d Previous non-aids related tumor. e Defined as HCV RNA detected. f Defined as HBcAb positive. g Two PLWH were on non-conventional ART. h Defined as a single HIV-RNA values between 50–999 copies/mL. i Defines as single HIV-RNA value equal to1,000 or at least two consecutive values between 50 − 1,000 copies/mL